Select the drug indication to add to your list

Viral infections
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:


Generic Name and Formulations:
Abacavir 600mg, dolutegravir 50mg, lamivudine 300mg; tabs.

ViiV Healthcare

Therapeutic Use:

Indications for TRIUMEQ:

HIV-1 infection in adults and pediatrics weighing ≥40kg.

Limitations Of use:

Not recommended alone in patients with resistance-associated integrase substitutions or suspected INSTI resistance due to insufficient dolutegravir dose in Triumeq in these subpopulations.

Adults and Children:

<40kg: not recommended. ≥40kg: 1 tab daily. Concomitant efavirenz, fosamprenavir/ritonavir, tipranavir/ritonavir, carbamazepine, rifampin: give additional dolutegravir 50mg separated by 12hrs from Triumeq.


Presence of HLA-B*5701 allele. Previous hypersensitivity reaction to any of the components. Concomitant dofetilide. Moderate or severe hepatic impairment.


See full labeling re: fatal hypersensitivity reactions with abacavir; discontinue as soon as suspected; do not restart. Evaluate for presence of HLA-B*5701 allele prior to starting therapy or reinitiation; if (+), abacavir is contraindicated; discontinue permanently if hypersensitivity cannot be ruled out even if other diagnoses are possible, regardless of HLA-B*5701 status. If stopped for reasons other than hypersensitivity, restart only if medical care can be readily accessed; monitor. Suspend if lactic acidosis or hepatotoxicity (eg, hepatomegaly and steatosis) occurs. Increased risk for worsening/development of elevated transaminases in patients with hepatitis B or C; monitor LFTs prior to starting, during therapy, and for at least several months after stopping treatment (discontinuing may exacerbate HBV infection). Myocardial infarction: consider CHD risk before starting therapy and minimize modifiable risk factors (eg, HTN, diabetes). Renal impairment (CrCl <50mL/min): not recommended; if lamivudine dose reduction is required, use individual components. Mild hepatic impairment: if abacavir dose reduction is required, use individual components. Elderly. Pregnancy. Nursing mothers: not recommended.


Ethanol may increase abacavir levels. Abacavir may increase clearance of methadone. Dolutegravir may be affected by drugs that induce or inhibit UGT1A1, CYP3A, UGT1A3, UGT1A9, BCRP, and P-gp enzymes or transporters. Avoid concomitant nevirapine, oxcarbazepine, phenytoin, phenobarbital, carbamazepine, St. John’s wort. Potentiates metformin (limit metformin dose to 1g/day); adjust metformin dose when stopping Triumeq; monitor blood glucose. Concomitant etravirine without atazanavir/ritonavir, darunavir/ritonavir, or lopinavir/ritonavir: not recommended. Concomitant efavirenz, fosamprenavir/ritonavir, tipranavir/ritonavir, carbamazepine, rifampin: requires extra dolutegravir dose (see Adults and Children). Concomitant cation-containing antacids or laxatives, sucralfate, buffered drugs, oral calcium/iron supplements, multivitamins; give Triumeq 2hrs before or 6hrs after; alternatively, oral calcium/iron can be used at the same time when taken with food. Monitor for toxicities (eg, hepatic decompensation) with IFN-α ± ribavirin (consider reducing dose or discontinue one or both drugs).

Pharmacological Class:

Nucleoside reverse transcriptase inhibitors (NRTIs) + integrase strand transfer inhibitor (INSTI).

Adverse Reactions:

Insomnia, headache, fatigue; immune reconstitution syndrome, fat redistribution; serious: hypersensitivity reactions, lactic acidosis, hepatomegaly with steatosis, hepatotoxicity (monitor).

Generic Availability:


How Supplied:


Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs